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The COMT inhibitors entacapone and tolcapone increase levodopa bioavailability in the plasma and increase its transport into the brain by However, they found a 45% increase in the striatal 18 F-dopa influx constant K i after entacapone when computed with an occipital reference input function. As the effect of entacapone was to increase the fraction of unmetabolised 18 F-dopa in plasma from 22 to 56% 90 minutes after injection, this 45% increase in K i represents a corresponding increase in striatal 18 F-dopa VD.
In a similar study in PD patients, 5 entacapone enhanced the striatal 18 F-dopa Ki (computed with an occipital reference input function) by 53.5% compared with placebo. However, changes in striatal 18 Fdopa uptake induced by entacapone are smaller in patients with advanced PD. This probably reflects a more severe loss of dopaminergic terminals, leading to impaired DA storage capacity in these patients. 6, 7 From these studies it can be concluded that entacapone has little effect on 18 F-dopa decarboxylation in the striatum and that its main pharmacological effect is related to reduced peripheral 3-O-methylation and increased availability of plasma 18 F-dopa to the brain.
Unlike entacapone, which is purely a peripheral COMT inhibitor, tolcapone is a mixed peripheral and central COMT inhibitor. 9, 10 The effect of tolcapone on COMT activity has been investigated in 12 PD patients with 18 F-dopa PET. 8 The study design comprised two PET Uitti et al. 19 scanned 10 untreated PD patients with 11 C-raclopride PET who were subsequently treated with either Sinemet ® (300mg of levodopa daily) or Sinemet ® CR (400mg of levodopa controlledrelease daily) for six months and then crossed over to the other levodopa preparation for a further six months. At baseline, these workers found striatal 11 C-raclopride binding to be increased in the untreated PD patients. When the patients were re-scanned after six months of levodopa treatment, there were no significant differences in striatal 11 C-raclopride binding in either group from baseline. After the second six-month period of levodopa treatment, again no differences in 11 C-raclopride binding were seen compared with baseline or between type of levodopa preparation. Clinically, both groups received similar symptomatic benefit following treatment, and none developed motor fluctuations. These workers concluded that striatal DA D 2 normalisation via downregulation in PD following levodopa exposure must take longer than 12 months.
Striatal DA D 1 receptor availability can be assessed with 11 C-SCH23390
PET and is preserved in untreated PD patients, but reduced by 20% in patients chronically exposed to levodopa. 14, 20 To summarise, exposure to oral levodopa appears to have only mild Figure 2) . Rises in synaptic DA levels translate into decreases in DA D 2 -receptor availability, which can be detected as reductions in 11 C-raclopride binding. 11 It has been estimated that a 10% reduction in 11 C-raclopride binding reflects a five-fold increase in synaptic DA levels. 21 This paradigm has recently been employed to assess the changes in synaptic DA levels after administration of a single dose of exogenous levodopa in PD patients (see Figure 3) .
Results from these studies have shown that striatal reductions in 11 Craclopride binding after a levodopa challenge become greater as motor disability increases and the disease progresses. [22] [23] [24] [25] Changes in 11 C-raclopride binding after oral administration of standard levodopa/carbidopa (250/25) were assessed in a group of PD patients with and without peak-dose dyskinesias.
24 Each patient received three 11 C-raclopride PET scans. The first one was performed at baseline with the patient 'off' medication and the others at one hour and four hours after levodopa. PD patients with dyskinesias had larger increases in synaptic DA levels than patients with stable response to levodopa one hour after administration, whereas there were no between-group differences at four hours. This finding suggests that peak-dose dyskinesias are associated with enhanced pulses of DA release induced by levodopa administration. In line with this interpretation, our group has recently reported that large putaminal 11 C-raclopride binding changes induced by Sinemet ® 275 were directly associated with higher dyskinesias scores during the scan session. 25 The increased synaptic DA levels that result from levodopa administration in dyskinetic and in more advanced PD patients probably reflect the reduced DA storage capacity of the severely affected putamen. However, another explanation could be the Although previous studies indicate that 11 C-raclopride PET represents an useful tool to investigate turnover of levodopa-induced synaptic DA in PD, this paradigm has not been applied to assess the efficacy of approaches to continuous levodopa delivery. Our group is currently testing the hypothesis that enteral (duodenal) infusions of levodopa provide stable and more prolonged synaptic levels of striatal DA compared with standard levodopa administration along with a sustained motor response.
Discussion
To our knowledge, there are no PET studies that have directly tested whether currently available drug approaches, which provide more sustained levodopa delivery, also provide stable and more prolonged synaptic levels of striatal DA along with a sustained motor response.
However, it is clear that PET has a great potential in this specific 
